50 projects
Status
Domain
Organization Type
A PRECLINICAL EVALUATION: VACCINATION AND EFFICACY AGAINST SARS-CoV-2
SARS-CoV-2, the causative factor of COVID-19, is endangering the world's health, prosperity and political crises are on the horizon. Nations worldwide had to take drastic measures to prevent catastrophes: strict confinement and hygienic measures have been undertaken to minimize the virus spread. Despite the control measures, the pandemic is inevitably damaging the economy due to a shutdown of public and business life, an overload of the healthcare systems, and the high case fatality rate of COVID-19. The global fight against COVID-19 has mobilized, and many provisional treatments are being ...
A dynamic model of the COVID-19 tuned for different countries: a systems-biological tool for the ...
A dynamic model of COVID-19 epidemics recently developed (video: https://youtu.be/lbsqJ1_WvmE, model: https://jjj.bio.vu.nl/models/westerhoff1/simulate/, ref: https://medrxiv.org/cgi/content/short/2020.03.29.20045039v1) will be tuned for different countries to analyze the effect of different measures in the anticipation of next epidemics. Models will be available for online simulations at JWS Online (https://jjj.bio.vu.nl/models/westerhoff1/simulate/), and used for the development of computer tutorials for systems biological studies.
A novel high throughput assay to measure plasma neutralizing activity against SARS-CoV2
To date, there is no vaccine and no specific antiviral agent against SARS-CoV-2. Because of hospital saturation, controversial drug efficiency and the risk of medicinal shortage, there is an urgent need for alternative treatment options. Passive (plasmapheresis) and active immunization (vaccine) approaches aim to provide or elicit a protective humoral immune response against SARS-CoV-2. This project aims to develop a high throughput assay to measure the neutralizing activity of COVID-19 patients. It will help characterize the antibody response against SARS-CoV-2, and select the sera with hi...
A unified web-based platform for viral phylogeny, proteomics and genomics research in real-time
We propose the development of an integrated web-based data exploration tool for genomics, proteomics, phylogeny, evolutionary and geographical data on SARS-CoV-2 samples from Luxembourg supporting researchers and physicians to gauge the potential impact of viral evolution on virulence and transmission dynamics but also the efficacy of molecular detection methods. Integrating different data sources and visualisation modes through a graphical web-interface will offer a unique perspective on the pathogen and serve as tools to assess potential imminent risks.
AICovIX - AI based diagnosis of Covid-19 from CT/X-Ray imaging
The gold standard for Covid-19 diagnosis is RT-PCR for SARS-CoV-2 from the upper airways. This method suffers from decreased accuracy in more severe disease stages affecting the lower airways. False negative PCR tests in severe cases impose a massive risk to the health system, promoting intra-hospital disease spread in the actual pandemic situation. Reports from China indicate false negative PCR from upper airway samples in severe Covid-19 pneumonia in more than 50% of the cases. Therefore, complementary tests for the detection of these dangerous cases are urgently needed. The value of che...
ARVIR
Arspectra's Augmented Reality glasses are modified in order to detect fever - the primary symptom of Covid19 infection - on distance. It enables the healthcare personnel organizing the overload of potential patients while staying at safe distances. It allows police forces, or airport security personnel to immediately detect a case of fever at airport, border, station, and public controls. These professionals are at the frontline fighting the spread of the epidemics, yet represent 30 % of the overall people getting infected. Providing detection on safe distance ARVIR reduces their ris...
An integrative network-based drug repurposing approach for COVID-19
We aim at analyzing the publicly available transcriptomics data generated by exposing human lung epithelial cells to SARS-CoV particles and measuring the differences in the gene expression. We will use a molecular network analysis approach to identify a set of key genes, that represent key regulators in the SARS-CoV gene expression signature. This signature will be filtered to distinguish pathological from protective responses and used to identify drugs that could potentially reverse pathological features of the disease phenotype based on the anti-correlation of known drug-response gene exp...
COVAMBU: Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COV...
The purpose of this Multi-centre, adaptive, randomized trial is to provide substantial evidence on the efficacy, or lack of efficacy and safety of treatments available in Luxembourg, given to COVID-19 positive-testing-patients who do not yet require hospitalization. Efficacy will be assessed through virological response and clinical outcomes.